Our mission is to create and lead cross-sector efforts that validate and qualify biomarkers and other drug development tools to accelerate better decision making for the development of new therapeutics and health technologies.
The Biomarkers Consortium (BC) convenes government, industry, patients and patient advocacy groups, and not-for-profit organizations to address one of the most pressing needs in the diagnosis and treatment of disease: the development and the seeking of regulatory approval for disease biomarkers and surrogates.
The core operations of the Biomarkers Consortium are supported through contributing membership. Organizations representing private industry (including the pharmaceutical, biotechnology, diagnostics, and information technology industries) and not-for-profit organizations (including associations, advocacy groups, trade organizations, and philanthropic organizations) that wish to support biomarkers development are eligible to become contributing members.
Read What Our Partners are Saying
New project will validate imaging tool that could help develop new Alzheimer’s disease treatments
New publication shows that blood-based tests could be the first step in screening for Alzheimer’s disease
FDA approves FNIH biomarker qualification plan for first surrogate endpoint in osteoporosis clinical trials
Reverse Engineering of Digital Measures: Inviting Patients to the Conversation